Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TransCode Therapeutics, Inc. RNAZ
$0.29
-$0.01 (-2.02%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4933767.00000000
-
week52high
2.85
-
week52low
0.28
-
Revenue
0
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-1.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 07 июн 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fitzgerald Thomas A | A | 100000 | 100000 | 12 дек 2022 г. |
| Dudley Robert Michael | A | 135000 | 135000 | 12 дек 2022 г. |
| Medarova Zdravka | A | 60000 | 60000 | 12 дек 2022 г. |
| Dudley Robert Michael | A | 893114 | 20000 | 14 сент 2022 г. |
| Calais Philippe | A | 9500 | 9500 | 22 июн 2022 г. |
| Marquet Magda | A | 9500 | 9500 | 22 июн 2022 г. |
| Manting Erik | A | 9500 | 9500 | 22 июн 2022 г. |
| Fitzgerald Thomas A | A | 139377 | 12000 | 16 июн 2022 г. |
| Dudley Robert Michael | A | 873114 | 2000 | 31 мая 2022 г. |
| Dudley Robert Michael | A | 871114 | 28000 | 27 мая 2022 г. |
Новостная лента
Why Is TransCode Therapeutics (RNAZ) Stock Up 45% Today?
InvestorPlace
01 февр 2023 г. в 08:03
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-RIGA, which is the company's immunotherapy candidate.
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
InvestorPlace
07 дек 2022 г. в 11:45
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won't pursue a plan to sell 12.5 million shares in a public offering.
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
GlobeNewsWire
07 ноя 2022 г. в 08:00
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its first-in-human clinical trial. The presentation will be webcast and an archived recording will be made available in the Investors' section of the TransCode Therapeutics website.
Why Is TransCode Therapeutics (RNAZ) Stock Up 30% Today?
InvestorPlace
26 окт 2022 г. в 11:01
It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ ) stock. That's because the company just disclosed the preclinical results of its proposed treatment for pancreatic cancer.